skip to Main Content

FDA grants priority review for Sage’s rapid-acting treatment for depression

Sage Therapeutics said Monday that U.S. regulators accepted a marketing application for its rapid-acting antidepressant and granted it priority review with a decision date set for early August.

The Food and Drug Administration will assess the efficacy and safety of the Sage drug, a once-daily pill called zuranolone, for the treatment of people with major depressive disorder and postpartum depression.

Continue to STAT+ to read the full story…

Back To Top